Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma.

Adv Sci (Weinh) · 2024 · PMC11321650 · PMID 38874532

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

On day 10, the combination therapy group showed a reduction in fluorescence intensity compared to the I1‐DXd group, although this difference did not reach statistical significance (I1‐DXd vs.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.